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Abstract
Economic evaluations from individual-level data are an important component of the
process of technology appraisal, with a view to informing resource allocation deci-
sions. A critical problem in these analyses is that both effectiveness and cost data
typically present some complexity (e.g. non normality, spikes and missingness) that
should be addressed using appropriate methods. However, in routine analyses, simple
standardised approaches are typically used, possibly leading to biased inferences.
We present a general Bayesian framework that can handle the complexity. We
show the benefits of using our approach with a motivating example, the MenSS
trial, for which there are spikes at one in the effectiveness and missingness in both
outcomes. We contrast a set of increasingly complex models and perform sensi-
tivity analysis to assess the robustness of the conclusions to a range of plausible
missingness assumptions.
This paper highlights the importance of adopting a comprehensive modelling
approach to economic evaluations and the strategic advantages of building these
complex models within a Bayesian framework.
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1 INTRODUCTION
Economic evaluation alongside Randomised Clinical Trials (RCTs) is an important and increasingly popular component of the
process of technology appraisal (1). The typical analysis of individual level data involves the comparison of two interventions
for which suitable measures of clinical benefits and costs are observed on each patient enrolled in the trial, often at different time
points throughout the follow up. For simplicity, we generically term the clinical benefits as “effectiveness” and thus indicate the
economic outcome variables as (푒, 푐).
Typically, effectiveness is measured through multi-attribute utility instruments (e.g. the EQ-5D 3L: http://www.euroqol.org),
the costs are obtained using clinic resource use records and both are summarised into cross-sectional quantities, e.g. Quality
Adjusted Life Years (QALYs). The main objective of the economic analysis is to combine the population average effectiveness
and costs and use the precepts of decision theory to determine the most “cost-effective” intervention, given current evidence, as
well as to assess the uncertainty in the decision-making process, induced by the uncertainty in the model inputs (2, 3, 4, 5, 6, 7,
8, 9, 10).
In routine analyses, trial-based Cost-Effectiveness Analyses (CEAs) are usually performed under a frequentist approach in
which the two outcome variables (푒, 푐) are modelled independently. Baseline adjustments are often included in the model using
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simple regression analyses (11, 12, 13). This, often implicitly, assumes normality for the underlying cost and effectiveness data,
or at least that the sample size is large enough for the population means to be (approximately) normally distributed. In addition,
almost invariably the relationship between the outcomes and the baseline characteristics is assumed to be linear.
There are several potential issues with this setting: firstly, the assumption of independence between costs and effectiveness is
often questionable.While this is a recognised problem in the CEA literature, particularly under a Bayesian framework (14, 15, 7),
and although it may introduce bias in the statistical modelling and, a fortiori, in the economic evaluation (14, 16), appropriate
methods to deal with correlation have historically found little application in routine analyses (17).
Secondly, because both costs and effectiveness are usually characterised by a large degree of skewness, the assumption of
normality is unlikely to hold and alternative approaches have been proposed in the literature. Examples include nonparametric
bootstrapping (18) and, particularly within a Bayesian approach, the use of more appropriate parametric modelling (15, 16).
Nonparametric bootstrapping mostly relies on using simple averages that often give similar results to those assuming normality
(19). Conversely, modelling based on different parametric distributions (e.g. Gamma for the costs and Beta for the QALYs)
often allows improvement in the model fit to the observed data and appropriately captures skewness.
Thirdly, data may exhibit spikes at one or both of the boundaries of the range for the underlying distribution. For example,
some patients in a trial may not accrue any cost at all (i.e. 푐푖 = 0), thus invalidating the assumptions for the Gamma distribution,
which is defined on the range (0,+∞). Similarly, we may observe individuals who are associated with perfect health, i.e. unit
QALY (20), which makes it difficult to use a Beta distribution, defined on the open interval (0, 1). A simple solution is to
add/subtract a small constant 휖 to the entire set of observed values for the cost/effectiveness variable, thus artificially re-scaling
it in the desired interval (21). Despite being very easy to implement, this strategy is potentially problematic as the results are
likely to be strongly affected by the actual choice of the scaling parameter 휖 and no clear guideline exists about the value to use
(e.g. 0.1, 0.01,…). In addition, when the proportion of these values is substantial, they may induce high skewness in the data and
the application of simple methods may lead to biased inferences (22). A more efficient solution suggested to handle this issue
is the application of hurdle models (23, 22, 24). These are mixture models defined by two components: the first one is a mass
distribution at the spike, while the second is a parametric model applied to the natural range of the relevant variable. Usually, a
logistic regression is used to estimate the probability of incurring a “structural” value (e.g. 0 for the costs, or 1 for the QALYs);
this is then used to weight the mean of the “non-structural” values estimated in the second component. Hurdle models have been
discussed and applied in CEA mainly for handling structural zero costs (25, 26, 24).
Finally, individual level data from RCTs are almost invariably affected by the problem of missing data. Numerous methods are
available for handling missingness in the wider statistical literature, each relying on specific assumptions whose validity must be
assessed on a case-by-case basis. Whilst some guidelines exist for performing CEAs in the presence of missing outcome values
(27), they tend not to be consistently followed in published studies (28, 29, 30, 31). Analyses that are limited to the observed
data (Complete Case Analysis, CCA) are inefficient and may yield biased inferences (32, 33, 26, 34). Multiple Imputation (MI;
35) is a more flexible method, which increasingly represents the de facto standard in clinical studies (36, 37). In a nutshell, MI
proceeds by replacing each missing data point with a value simulated from a suitable model.푀 complete (i.e. without missing
data) replicates of the original dataset are thus created, each of which is then analysed separately using standard methods.
The individual estimates are pooled using meta-analytic tools such as Rubin’s rules (35), to reflect the inherent uncertainty in
imputing the missing values. For historical reasons, as well as on the basis of theoretical considerations, the number of replicated
datesets푀 is usually in the range 5-10 (35, 38, 39).
As a consequence of the separation between the imputation and the analysis steps, MI requires the property of congeniality, i.e.
the imputation model needs to be specified as equally or less restrictive than the analysis model (40). In addition, in many
applications, MI is based upon assuming a Missing At Random (MAR) mechanism, i.e. the observed data can explain fully
the reason for why some observations are missing. However, this may not be reasonable in practice (e.g. for self-reported
questionnaire data) and it is important to explore whether the resulting inferences are robust to a range of plausibleMissing Not
At Random (MNAR) mechanisms, which cannot be explained fully by the observed data. Neither MAR nor MNAR assumptions
can be tested using the available data alone and thus it is crucial to perform sensitivity analysis to explore how variations in
assumptions about the missing values impact the results (41, 42).
Building on the existent literature, we show howmodels that simultaneously account for different potential sources of bias can
be efficiently specified under a full Bayesian framework, which has several advantages in comparison to a frequentist counterpart,
specifically in health care technology assessments (10, 7). Firstly, by virtue of its modular nature, Bayesian modelling is very
flexible, which means that a basic structure can be relatively easily extended to account for the increasing complexity required
to formally allow for the several features described above. We exploit this in §3. In addition, the Bayesian approach naturally
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allows for the principled incorporation of external evidence (e.g. expert opinions) through the use of prior distributions. This
is often crucial for conducting sensitivity analysis to a plausible range of missingness assumptions including MNAR (43, 44),
particularly when the evidence produced by the current study is limited, as is the case for small pilot trials, whose objective is
to aid decision making about larger investments. Examples include the conduct of a full-scale trial, or the introduction in the
market of a new cancer drug, based on the extrapolation of survival data produced over a short follow up.
Moreover, we note that MI can be considered as an approximation to a full Bayesian analysis on different levels. First, MI
separates the imputation and analysis steps in two estimation procedures while, within a full Bayesian approach, the parameters
of interest are estimated simultaneously with the imputation of the missing values and no additional analysis or ad hoc pooling
is necessary. Even though it has been shown that MI performs well in most standard situations, when the complexity of the
analysis increases, a full Bayesian approach is likely to be a preferable option as it naturally allows the propagation of uncertainty
to the wider economic model and to perform sensitivity analysis. Second, due to the small number of replicates that are kept in
practice, MI can be thought of as a fully Bayesian analysis based on a few simulations. Interestingly, the often-quoted objection
to Bayesian modelling, i.e. that it is too computationally intensive in comparison to simpler frequentist counterparts, is likely
to dissolve in the presence of extremely complex models, which would require tailor-made routines for the optimisation of
non-standard multivariate likelihood functions, thus effectively surrendering their computational advantage over intensive but
efficient sampling methods such as Markov Chain Monte Carlo (MCMC).
The main contribution of this work is to provide a unified framework that allows jointly tackling the features in CEA discussed
above. We use a real case study based on a small pilot trial as our motivating example. Starting from the original analysis, we
progressively expand our basic model. We specifically focus on appropriately modelling spikes at the boundary and missingness,
as they have substantial implications in terms of inferences and, crucially, cost-effectiveness results. The paper is structured as
follows: in §2 we present the case study and describe the data. §3 defines the general structure of the statistical model used
in the analyses and how it can be tailored to deal with the different features affecting the data. Initially, for simplicity, we
present each model under a complete case scenario that will then be extended to account for missingness. §4 compares the
results from three alternative models under both a complete cases and all cases scenario assuming MAR. The robustness of the
results to alternative MNAR assumptions is then explored. §5 summarises the inferences for each model from a decision-maker
perspective and compares their implications in terms of cost-effectiveness. §6 discusses the proposed framework and suggests
some improvements for future work. Finally, the Appendix includes additional material related to model assessment and the
computer code for our analysis.
2 CASE STUDY: THE MENSS TRIAL
We use as a motivating example the MenSS trial (45), a pilot RCT conducted in the UK public care sector to evaluate the cost-
effectiveness of a new interactive digital intervention (the Men’s Safer Sex website, MenSS). This new intervention provides
individually tailored advice on barriers to condom use to reduce the incidence of Sexually Transmitted Infections (STIs) in
young men. A total of 159 men aged 16 years and over with female sexual partners and recent unprotected sex or suspected
acute STI were recruited from three English sexual health clinics. Participants were randomised to receive either usual clinical
care only (comparator, 푛1 = 75), or a combination of usual care and the MenSS website (active intervention, 푛2 = 84). Sexual
health related resource use was collected via participant responses to questionnaires at 3, 6 and 12 months. For each individual
푖, utility scores 푢푖푗 were computed based on a generic health related quality of life questionnaire, the EQ-5D 3L, collected at
baseline (푗 = 0) and then at 3, 6 and 12 months (푗 = 1, 2, 퐽 = 3). QALYs and total costs (measured in £) were calculated by
combining the utilities 푢푖푗 and costs 푐푖푗 collected at each time point as
푒푖 =
퐽∑
푗=1
(푢푖푗 + 푢푖 푗−1)
훿푗
2
and 푐푖 =
퐽∑
푗=1
푐푖푗 , (1)
where 훿푗 = Time푗−Time푗−1Unit of time is the fraction of the time unit (12 months) between consecutive measurements, e.g. 훿2 = (6 months −3 months)∕12 months = 0.25. For the utilities, this approach is often referred to as the Area Under the Curve (AUC; 46).
The number of participants completing utility and cost questionnaires at every time point was 27 (36%) and 19 (23%) for the
control and intervention group, respectively. Figure 1 shows the histograms of the distributions of the complete case QALYs
and costs in the control (panels a-b) and intervention (panels c-d) group, respectively.
FIGURE 1 HERE
4 Andrea Gabrio ET AL
The data clearly present some of the features described in §1. A relatively high degree of skewness characterises the empirical
distributions of QALYs and costs in both treatment groups. In particular, the substantial proportion of individuals incurring a
perfect health status (which we term “structural ones”) observed in both control (33%) and intervention (42%) groups effectively
induces spikes at 1 in the QALYs. Finally, a large proportion of missingness characterises both cost and utility data due to poor
follow-up rates. A statistical summary of the observed cases and missingness levels for the utility and cost variables by follow
up period is shown in Table 1 (recall that baseline data are collected for the utilities only).
TABLE 1 HERE
The original analysis was performed under a frequentist approach using standard OLS regression (45). Baseline utility regres-
sion adjustment was incorporated in the model, assuming MAR for all variables and restricting the analysis to the complete
cases. However, most of the features described in §1 were not explicitly taken into account.
3 MODELLING FRAMEWORK
In this section, we firstly present our general modelling framework for cost-effectiveness data. The model improves the typical
approach used in routine analyses by accounting for correlation between the outcomes. Then it is extended to handle structural
values and missing data using three alternative specifications with increasing complexity. Throughout, we refer to our motivating
example to demonstrate the flexibility of our full Bayesian approach in dealing with the idiosyncrasies highlighted above; we
also note that these are likely to be encountered in many practical cases, thus making our arguments applicable in general.
Assume that some patient-level data are collected from a trial on 푖 = 1,… , 푛 individuals who are randomly allocated to
either a control (푡 = 1) or intervention (푡 = 2) group, with sample sizes 푛1 and 푛2, respectively. We denote by 푒푖푡 and 푐푖푡 the
effectiveness and cost outcome variables for the 푖−th person in group 푡 of the trial. To simplify the notation, unless necessary,
we suppress the treatment subscript 푡.
To account for correlation between the outcomes, in general we can specify the joint distribution 푝(푒, 푐) as:
푝(푒, 푐) = 푝(푐)푝(푒 ∣ 푐) = 푝(푒)푝(푐 ∣ 푒), (2)
where, for example, 푝(푒) is the marginal distribution of the effectiveness and 푝(푐 ∣ 푒) is the conditional distribution of the costs
given the effectiveness (15). Note that while it is possible to use interchangeably either factorisation in Equation 2, without loss
of generality, we describe our analysis in the following through a marginal distribution for the effectiveness (QALYs) and a
conditional distribution for the costs.
For each individual we consider a marginal distribution 푝(푒푖 ∣ 휽푒) indexed by a set of parameters 휽푒 comprising a location
휙푖푒 and a set of ancillary parameters 흍푒 typically including some measure of marginal variance, 휎2푒 . We can model the locationparameter using a generalised linear structure, e.g.
푔푒(휙푖푒) = 훼0 [+…],
where 훼0 is the intercept and the notation [+…] indicates that other terms (e.g. quantifying the effect of relevant covariates)
may or may not be included in the model. In the absence of covariates or assuming that a centered version 푥∗푖 = (푥푖 − 푥̄) is used,the parameter 휇푒 = 푔−1푒 (훼0) represents the population average effectiveness.For the costs, we consider a conditional model 푝(푐푖 ∣ 푒푖,휽푐), which explicitly depends on the effectiveness variable, as well as
on a set of quantities 휽푐 , again comprising a location and ancillary parameters. Note that in this case 흍푐 includes a conditional
variance 휏2푐 , which can be typically expressed as a function of the marginal variance 휎2푐 (15, 7). The location can be modelledas a function of the effectiveness variable as:
푔푐(휙푖푐) = 훽0 + 훽1(푒푖 − 휇푒) [+…].
Here, (푒푖 − 휇푒) is the centered version of the effectiveness variable, while 훽1 quantifies the correlation between costs and
effectiveness. Assuming other covariates are either also centered or absent, 휇푐 = 푔−1푐 (훽0) is the population average cost.Figure 2 shows a graphical representation of the general modelling framework described above. The effectiveness and cost
distributions are represented in terms of combined “modules” — the blue and the red boxes — in which the random quantities
are linked through logical relationships. This ensures the full characterisation of the uncertainty for each variable in the model.
Notably, this is general enough to be extended to any suitable distributional assumption, as well as to handle covariates in either
or both the modules.
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FIGURE 2 HERE
In the rest of the section, we present three alternative specifications of the general structure depicted in Figure 2 to model
effectiveness and cost data. These are 1) Normal marginal for the effectiveness and Normal conditional for the costs (which is
identical to a Bivariate Normal distribution for the two outcomes); 2) Beta marginal for the effectiveness and Gamma conditional
for the costs; and 3) Hurdle Model. First, we present each assuming a complete cases scenario and then extend the structure
to all cases (complete and partially observed), considering both MAR (for all models) or alternative MNAR scenarios (for the
Hurdle Model only).
3.1 Complete Cases
3.1.1 Bivariate Normal
Arguably, the easiest way of jointly modelling two variables is to assume Bivariate normality, which in our context can be
factorised into marginal and conditional Normal distributions for 푒푖 and 푐푖 ∣ 푒푖. This is the closest modelling structure to those
underpinning a typical frequentist analysis, while also accounting for potential correlation between the outcomes.
In line with current recommendations (and the original analysis of the MenSS trial), we adjust for the baseline utilities —
using a centered version (푢푖0− 푢̄0). We model 푒푖 ∣ 휽푒 ∼ Normal(휙푖푒, 휎2푒 ), using an identity link function for the location parameter
푔푒(휙푖푒) = 휙푖푒 = 훼0 + 훼1(푢푖0 − 푢̄0).
Here, the parameter 훼1 quantifies the impact of the centered baseline utilities on the QALYs, while 휇푒 = 훼0 and 휎2푒 represent themarginal (population level) mean and variance, respectively.
As for the costs, we model 푐푖 ∣ 푒푖,휽푐 ∼ Normal(휙푖푐 , 휏2푐 ), where the conditional mean and variance are defined as
푔푐(휙푖푐) = 휙푖푐 = 훽0 + 훽1(푒푖 − 휇푒) and 휏2푐 = 휎2푐 − 휎2푒훽21 .
The model parameters are thus 휽푒 = (훼0, 훼1, 휎2푒 ) and 휽푐 = (훽0, 훽1, 휇푒, 휎2푐 , 휎2푒 )— note that the marginal mean and variance of theeffectiveness link the two modules and therefore feature in both sets of parameters.
The model is completed by assigning suitable prior distributions to the elements of 휽 = (휽푒,휽푐); for example, independent
Normal priors can be assumed for the regression parameters, while Uniform or Half-Cauchy priors can be assigned on the scale
of the standard deviations (47).
3.1.2 Beta-Gamma
The second model we consider assumes a Beta marginal for the QALYs and a Gamma conditional for the costs. In particular,
we parameterise the Beta distribution in terms of the mean 휙푖푒 and the scale parameter 휏푖푒 =
(
휙푖푒(1−휙푖푒)
휎2푒
− 1
)
as 푒푖 ∣ 휽푒 ∼
Beta (휙푖푒휏푖푒, (1 − 휙푖푒)휏푖푒) and model the location as
푔푒(휙푖푒) = logit(휙푖푒) = 훼0 + 훼1(푢푖0 − 푢̄0).
The costs are modelled as 푐푖 ∣ 푒푖,휽푐 ∼ Gamma
(
휙푖푐휏푖푐 , 휏푖푐
), where the shape parameter is defined as the product of the location
휙푖푐 and the rate 휏푖푐 . The generalised linear model for the location is
푔푐(휙푖푐) = log(휙푖푐) = 훽0 + 훽1(푒푖 − 휇푒).
The marginal means for the QALYs and total costs can then be obtained using the respective inverse link functions
휇푒 =
exp(훼0)
1 + exp(훼0) and 휇푐 = exp(훽0).
Notice that, in comparison to the Bivariate Normal of §3.1.1, the Beta-Gamma model reflects more closely the range and
skewness of the observed data. Nevertheless, this modelling structure also fails to directly account for the structural values,
e.g. unit QALYs. In the presence of structural values, it is necessary to rescale the observed data, e.g. by applying the Beta
model to 푒∗푖 = 푒푖 − 휖 for some 휖 → 0.The model is again completed by placing suitable priors on the parameters. Typically, it is easier to encode genuine prior
information on the natural scale of the parameters (24, 48). For example, we can use independent Normal priors for the regression
coefficients (훼1, 훽1), Uniform priors on suitable scales for (휇푐 , 휇푒) and a Uniform or Half-Cauchy prior for 휎푐 . Notice, however,
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that a little more care is needed in defining a prior distribution for 휎푒. In fact, by the mathematical properties of the Beta
distribution, the variance is bounded by a function of the mean
휎2푒 ≤ 휇푒(1 − 휇푒) = 휐.
Consequently, we can place an informative prior on the standard deviation 휎푒 ∼ Uniform(0,
√
휐), which coupled with a prior
for 휇푒 induces a suitable prior for 휏푒 as well. Note that even by starting with vague distributions for (휇푒, 휎푒), the resulting prior
for the Beta scale 휏푒 may not be vague at all.
3.1.3 Hurdle Model
To overcome the limitations of the model in §3.1.2 in terms of the structural ones, we expand it to a hurdle version. Specifically,
for each subject in the trial 푖 = 1,… , 푛we define an indicator variable 푑푖푒 taking value 1 if the 푖−th individual is associated with
a unit QALYs (푒푖 = 1) and 0 otherwise (푒푖 < 1). This is then modelled as
푑푖푒 ∶= 핀(푒푖 = 1) ∼ Bernoulli(휋푖푒)
logit(휋푖푒) = 훾0 + 훾1(푢푖0 − 푢̄0) [+…], (3)
where 휋푖푒 is the individual probability of unit QALYs, which is estimated on the logit scale as a function of a baseline parameter
훾0 and the centred baseline utilities, whose effect is captured by the parameter 훾1. As for the effectiveness and cost models,
other covariates can be additively included in the model of 푑푖푒. We specifically distinguish the baseline utilities from any other
covariate as they are likely to be particularly informative in predicting whether an individual is associated with a structural one in
the QALYs. All the logistic regression parameters should be given suitable prior probability distributions (e.g. Normal). Within
this framework, the quantity
휋̄푒 =
exp(훾0)
1 + exp(훾0) (4)
represents the estimated marginal probability of unit QALYs. The parameters 휋̄푒 and (1 − 휋̄푒) in effect represent the weights
used to mix the two components.
Depending on the value of 푑푖푒, we can partition the observed data on the QALYs into two subsets. In the first subset, defined
as the 푛1 subjects for whom 푑푖푒 = 1, we define a variable 푒1푖 = 1. Conversely, the second subset consists of the 푛<1 = (푛 − 푛1)subjects for whom 푑푖푒 = 0 and for these individuals we define a variable 푒<1푖 . Because this is less than 1, we can model it directlyusing a Beta distribution characterised by an overall mean 휇<1푒 , in line with the specification we have shown in §3.1.2. Using theestimated value for 휋̄푒 from Equation 4, we can compute the overall population average effectiveness measure in both treatment
groups 휇푒푡 as the linear combination
휇푒푡 = (1 − 휋̄푒푡)휇<1푒푡 + 휋̄푒푡.
In the absence of structural zeros, the conditional model for the costs is exactly as specified in §3.1.2.
3.2 All Cases
When missingness occurs in the QALYs and cost variables, no change to the model structure is required under MAR for both
the Bivariate Normal and Beta-Gamma specifications. For the Hurdle Model, when 푒푖 is missing, it is not possible to directly
define the value for 푑푖푒. However, unit QALYs can only be observed if 푢푖푗 = 1 for all time points 푗 = 0,… , 퐽 . Consequently,
if an individual 푖 is such that 푢푖푗 is missing at some time point 푗 and 푢푖푗 ≠ 1 at any other time point, then by necessity 푑푖푒 = 0.
However, for all individuals having 푢푖푗 = 1 at all observed time points but with at least one missing value at some other time
point, then 푑푖푒 is unknown.
Incomplete covariates need to be explicitly modelled to impute their missing values. For simplicity, we consider the case
where the only covariate included in the model is the baseline utility; however, the same approach can be extended to any other
type of partially-observed covariates. In the Bivariate Normal and the Beta-Gamma formulations, we can handle missingness in
푢푖0 by assuming a suitable model. One simple choice is to assume the same distribution for 푢푖0 as for the outcome 푒푖, i.e. Normal
or Beta, respectively — for example, Appendix A shows the implementation for the Beta-Gamma model.
Similarly to §3.1.3, we can formulate another hurdle model for 푢푖0. More specifically, first we specify a model for the indi-
viduals with a non-unit utility value. Again, a simple solution is to base this on the same distributions assumed for the QALYs.
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Secondly, we estimate the probability of observing a structural one in the utilities as
푑푖푢 ∶= 핀(푢푖 = 1) ∼ Bernoulli(휋푖푢)
logit(휋푖푢) = 휂0 [+…]
where 푑푖푢 is the indicator variable for the structural ones in the baseline utilities.
3.2.1 Sensitivity analysis (MNAR)
Finally, Hurdle Models also offer a convenient framework for exploring the robustness of the results to some departures from
MAR and therefore allow to perform a simple type of sensitivity analysis to the missingness assumptions. Two relevant cases
are:
a) the individuals for whom utility values are missing throughout the follow up, i.e. 푢푖푗 = NA for all 푗 = 1,… , 퐽 ;
b) the individuals for whom all the observed utilities are equal to 1, but with at least one time point 푗 at which 푢푖푗 = NA.
For both these cases, it is impossible to compute the value of the indicator 푑푖푒 according to the information from the observed
data. However, we can arbitrarily set the value of 푑푖푒 to either 1 or 0 using different configurations, e.g. by varying the number
of structural values potentially observed in a given scenario. Since these configurations are based on assumptions about the
missing values that cannot be verified from the data at hand (but are in fact arbitrarily set by the experimenter), they effectively
represent a way to assess the robustness of the results to some departures from MAR.
In the MenSS trial, there are 푛∗1 = 13 (12%) individuals in the control and 푛∗2 = 22 (26%) in the intervention group whofall within case a or b. Thus, we perform sensitivity analysis by defining a set of alternative MNAR assumption scenarios for
these individuals and assess the robustness of the results across them. The four different scenarios considered are summarised
in Table 2 :
TABLE 2 HERE
We choose these scenarios in order to assess how different “extreme” combinations of the number of potential structural ones
in the intervention and control group can impact the results.
4 RESULTS
We fitted all models using JAGS, (49), a software specifically designed for the analysis of Bayesian models using Markov Chain
Monte Carlo (MCMC) simulation, which can be interfaced with R through the package R2jags (50). Samples from the posterior
distribution of the parameters of interest generated by JAGS and saved to the R workspace are then used to produce summary
statistics and plots. We ran two chains with 20,000 iterations per chain, using a burn-in of 10,000, for a total sample of 20,000
iterations for posterior inference. For each unknown quantity in the model, we assessed convergence and autocorrelation of the
MCMC simulations using diagnostic measures such as the potential scale reduction factor and the effective sample size (51).
The total running time required for the models to produce representative samples from the posterior distributions of interest
ranged from 5 to 10 minutes.
Alternative prior distributions were considered to assess the sensitivity of the inferences to different vague prior specifications
(e.g. both Uniform and Half-Cauchy distributions for the standard deviations or different values for the variance of normally-
distributed regression parameters). Results were robust to these specifications. Although the HurdleModel as described in §3.1.3
cannot be directly written in JAGS, it can be implemented using a simple “coding trick”. Appendix A presents all the technical
details and the JAGS script.
4.1 Complete and All Cases (MAR)
Following the original analysis, we first consider only the complete cases and adjust for baseline utilities at the mean level for
the QALYs in each model. For the Hurdle Model, in addition to the centered baseline utility, we include in the linear predictor of
Equation 3 three more categorical covariates (age, ethnicity and employment status). These are used to estimate the probability
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of structural ones in the QALYs.We then extend the framework to all cases underMAR, where the baseline utilities are explicitly
modelled as detailed in §3.2 and again as functions of age, ethnicity and employment status.
Figure 3 shows the posterior distributions of the mean QALYs and costs for both treatment groups under a complete (red)
and all (blue) cases scenario for each model, assuming MAR.
FIGURE 3 HERE
The posterior distributions of the mean QALYs (panels a-b) present some discrepancies between the complete and all cases
scenarios, with magnitude varying according to the treatment group and model considered. In general, the results for all cases
are lower in the control group and higher in the intervention group in comparison to those obtained using the complete cases.
As for the mean costs (panels c-d), the results associated with a Gamma distribution are substantially more skewed compared
to those obtaining using the Normal model, especially in the intervention group. In addition, the Gamma model typically leads
to mean estimates that are systematically lower under the all cases scenario.
We compare the fit of the different models using the Deviance Information Criterion (DIC; 52). The DIC is a measure of
comparative predictive ability based on the model deviance and a penalty for model complexity.When comparing a set of models
based on the same data, the one associated with the lowest DIC is the best-performing, among those assessed. There are different
ways of constructing the DIC in the presence of missing data, which means that its use and interpretation are not straightforward
(53, 54). In our analysis, we consider a DIC based on the observed data and calculated only for the modules that are in common
between the models, i.e. excluding the contribution from the structural indicators for the Hurdle Model. The Bivariate Normal
model is always associated with the highest DIC under both a complete and all cases scenarios (536 and 445). The Beta-Gamma
(386 and 60) and, especially, the Hurdle model (−50 and −2419) substantially improve the model fit to the observed data.
4.1.1 Imputations under MAR
Figure 4 depicts the observed QALYs in both treatment groups (indicated with black crosses) as well as summaries of the
posterior distributions for the imputed values, obtained from each model. Imputations are distinguished based on whether the
corresponding baseline utility value is observed or missing (blue or red lines and dots, respectively) and are summarised in terms
of posterior mean and 90% Highest Posterior Density (HPD) intervals.
FIGURE 4 HERE
There are clear differences in the imputed values and corresponding credible intervals between the three models in both
treatment groups. Neither the Bivariate Normal nor the Beta-Gamma models produce imputed values that capture the struc-
tural one component in the data. In addition, as to be expected, the Bivariate Normal fails to respect the natural support for the
observed QALYs, with many of the imputations exceeding the unit threshold bound. These unrealistic imputed values high-
light the inadequacy of the Normal distribution for the data and may lead to distorted inferences. Conversely, imputations under
the Hurdle Model are more realistic, as they can replicate values in the whole range of the observed data, including the struc-
tural ones. Imputed unit QALYs with no discernible interval are only observed in the intervention group due to the original data
composition, i.e. individuals associated with a unit baseline utility and missing QALYs are almost exclusively present in the
intervention group.
4.2 Sensitivity Analysis (MNAR)
For each of the alternativeMNAR scenarios described in §3.2.1, as well as for the analysis underMAR, Figure 5 shows posterior
density strips for the structural one probability 휋̄푒 and the marginal mean QALYs 휇푒, in the control (red) and intervention
(blue) groups.
FIGURE 5 HERE
Estimates under MAR indicate that the new intervention is associated with a probability of observing a structural one and
a mean QALYs that are on average higher compared to the control. Although similar results are obtained under MNAR1, the
estimated quantities are highly unstable across the other three MNAR scenarios. Specifically, under MNAR2 the probability of
structural ones is substantially reduced in both groups and induces a zero mean difference in the QALYs. Under MNAR3 and
MNAR4 the differences between the estimated probabilities and mean QALYs in the two groups are increased in magnitude
and lead to opposite mean differentials.
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5 ECONOMIC EVALUATION
We complete the analysis by assessing the cost-effectiveness of the new intervention with respect to the control, comparing the
results of the different models under MAR (§ 4.1) and the alternative MNAR scenarios explored for the Hurdle Model (§ 4.2).
We specifically rely on the examination of the Cost-Effectiveness Plane (CEP; 55) and the Cost-Effectiveness Acceptability
Curve (CEAC; 56) to summarise the economic analysis.
FIGURE 6 HERE
The CEP (Figure 6 , panel a) is a graphical representation of the joint distribution for the population average effectiveness
and costs increments, indicated respectively asΔ푒 = (휇푒2−휇푒1) andΔ푐 = (휇푐2−휇푐1), under the three model specifications (light
red for the Bivariate Normal, light green for the Beta-Gamma and light blue for the Hurdle Model). The slope of the straight line
crossing the plane is the “willingness to pay” threshold (often indicated as 푘), and can be considered as the amount of budget the
decision-maker is willing to spend to increase the health outcome of one unit and effectively is used to trade clinical benefits for
money. Points lying below this straight line fall in the so-called sustainability area (7) and suggest that the active intervention is
more cost-effective than the control. This is because in this area the new intervention is either more effective and less expensive
(in the South-Eastern quadrant) or it produces an increase in benefits that more than offsets the increase in the costs (points in
the North-Eastern quadrant below the line). In the graph, which for simplicity only displays the results associated with the all
cases under MAR, we also show the Incremental Cost-Effectiveness Ratio (ICER) computed under each model, as darker colour
dots. This is defined as
ICER = E[Δ푐]E[Δ푒]
and it quantifies the cost per incremental unit of QALYs. For all three models more than 70% of the samples fall in the sus-
tainability area and are associated with negative ICERs, suggesting that the intervention can be considered as cost-effective by
producing a QALYs gain at virtually no extra costs, or even saving money.
The CEAC (Figure 6 , panel b) is obtained by computing the proportion of points lying in the sustainability area upon varying
the willingness to pay threshold 푘. Based on general recommended guidelines (1), we consider a range for 푘 up to £30,000 per
QALY gained. The CEAC estimates the probability of cost-effectiveness, thus providing a simple summary of the uncertainty
associatedwith the “optimal” decision-making suggested by the ICER. For eachmodel, the results underMAR are reported using
solid lines with different colours, i.e. red for the Bivariate Normal, green for the Beta-Gamma and blue for the Hurdle Model. In
addition, the results associated with the four MNAR scenarios are reported using different types of dashed lines. Under MAR,
for the Bivariate Normal and Beta-Gamma models the CEACs indicate the cost-effectiveness of the new intervention with a
probability above 0.8 for most values of 푘. Conversely, under the Hurdle Model, the curve is shifted downward by 0.24 and 0.16
with respect to the Bivariate Normal and Beta-Gamma models, respectively, and suggests a more uncertain conclusion. Perhaps
unsurprisingly, none of these results is robust to the alternative MNAR scenarios explored. The CEAC plot clearly shows a large
sensitivity of the cost-effectiveness probability with respect to the assumed number of structural ones in both treatment groups.
Indeed, the curves span a huge probability range from 0.2 under MNAR4 to 1 under MNAR3. This implies a considerable
change in the output of the decision process and severely undermines the validity of the conclusions obtained under MAR.
6 DISCUSSION
In CEAs alongside RCTs, analysts typically rely on standard models that ignore or at best fail to properly account for poten-
tially important features in the data, such as the correlation between costs and effectiveness, skewness in the distribution of the
observed data, the presence of structural values and, almost invariably, missing data. In this paper, we have presented a general
Bayesian framework that is able to overcome these problems.
The analysis of our motivating example shows notable variations in the results, compared with those of the original analy-
sis. Accounting for the structural ones and missingness uncertainty has a considerable impact on the cost-effectiveness of the
new intervention and future research prioritisation. Our results are obtained with specific reference to the motivating example.
However, the MenSS study is very much representative of the “typical” dataset used in CEAs alongside RCTs. Thus, it is highly
likely that the same features (and potentially the same contradictions in the results, upon varying the complexity of the mod-
elling assumptions) apply to many real cases. This is a very important, if somewhat overlooked problem, as it can thwart the
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validity of simplistic models that, while established among practitioners, may lead to misleading cost-effectiveness conclusions
and bias the decision-making process.
Missing data pose a serious threat to the economic evaluation as, when confronted with a partially-observed dataset, each
analysis makes assumptions about the missing values that cannot be verified from the data at hand. Any measure of fit or
predictive accuracy, such as the DIC or Posterior Predictive Checks (51), can only provide information about the observed data
and therefore tell just part of the story (53, 54). Thus, the use of sensitivity analysis to explore the impact on the results of different
plausible missingness assumptions, including MNAR, becomes essential. The Bayesian approach naturally allows to perform
these assessments through the incorporation of external evidence (e.g. expert opinions) in the model using prior distributions
while ensuring consistency and the correct propagation of uncertainty throughout the model.
We have demonstrated one possible way of assessing the robustness of the results to a range of MNAR scenarios. Even
though our approach assumes specific MNAR values (structural ones), it has the advantage of being easy to implement and
offers a starting point to investigate MNAR assumptions more thoroughly. Specifically, if one of these scenarios is thought to be
more realistic, then it can be explored using more advanced methods that explicitly allow for variability in the MNAR values,
e.g. Selection Models or Pattern Mixture Models (43, 44, 42).
Finally, a potentially relevant question concerning missing variables derived from repeated questionnaires, e.g. EQ-5D, is
whether imputation should be carried out at the time scores (utilities) or total scores (QALYs) level. The two approaches may
substantially differ as imputing at the time scores level typically requires that the longitudinal structure of the data is appropriately
modelled. Similar issues apply to multi-item questionnaires. The performance of these two alternative imputation strategies has
only recently been compared in the health economic literature and further research is needed (57, 58, 59).
In conclusion, in this work we have presented a flexible Bayesian analytic framework that can: a) jointly model costs and
effectiveness; b) account for skewness and structural values; and c) assess the robustness of the results under a set of differing
plausible missingness assumptions. These are typical features affecting CEA individual-level data that should be simultane-
ously addressed to avoid biased results, which may in turn lead to misleading cost-effectiveness conclusions. The availability of
methodological and practical tools such as the ones presented in this paper have the potential to improve the work of modellers
and regulators alike, thus advancing the fields of economic evaluation of health care interventions.
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A MODEL CODE AND IMPLEMENTATION
A.1 Implementation “trick”
The model described in §3.1.3 uses a different sampling distribution for the QALYs, depending on the observed value of the
indicator 푑푖푒
푒푖 ∣ 푑푖푒 ∼
{
푝(푒푖 ∣ 푑푖푒 = 0) = 푝(푒푖 ∣ 휽<1), if 푒푖 < 1
푝(푒푖 ∣ 푑푖푒 = 1) = 푝(푒푖 ∣ 휽1), if 푒푖 = 1,
where the model for 푒푖 = 1 is degenerate at a point mass at 1, while that for 푒푖 < 1 is defined in terms of a Beta distribution. We
can conveniently re-write this more succinctly and with specific reference to our case as
푒푖 ∼ Beta
(
휙푑푖푒푖푒 휏
푑푖푒
푖푒 ,
(
1 − 휙푑푖푒푖푒
)
휏푑푖푒푖푒
)
.
If we set 휙1푖푒 = 1 and select 휏1푖푒 in order to induce a variance as close to 0 as possible, the two specifications are identical.Unfortunately, it is not possible to do so in the BUGS/JAGS language, because the Beta distribution is specified in the open interval
(0, 1) and thus setting 휙1푖푒 = 1 implies that 휏1푖푒 = 0, which is not allowed.However, the required behaviour is very closely mimicked if we define our model with
logit(휙1푖푒) = 훼10 [+…]
and set 훼10 = logit(0.999999) and 휎푒 ≈ 0, which implies 휇푒 ≈ 1 with virtually no uncertainty. In other words, we can specifyextremely informative priors on the parameters 휽1 so that the implied distribution for the structural ones components of the
mixture is concentrated around 1 with essentially no uncertainty. More importantly, with such a prior no amount of data can
modify the posterior. The critical aspect of this strategy, however, is that inferences may be potentially sensitive to the way such
priors are specified, that is whether a small variation in the hyperprior values can affect the posterior estimates.
In fact, the estimation of the other parameters is not really affected by this choice, provided that the encoded prior really
induces the variance towards zero. It is also plausible that different values for 휎1푒 have an impact on measures of model fit, suchas the DIC. This is essentially due to the fact that the population is really comprised of two groups, one of which shows QALYs
that are identically one. Thus, the closer the approximation to zero for the variance the better the fit to the observed data and
therefore the smaller the resulting DIC.
With this in mind, we have used different values for 휎1푒 to assess the impact on the mean QALYs estimates. Fixing the value ofthe mean for the ones group to 휇1푒 = 0.999999 corresponds to an upper bound for the standard deviation of 0.0001 (see §3.1.2).We have explored a range of possibilities by progressively decreasing this value and assessed their impact on posterior results.
Figure 7 shows the sensitivity of the inferences across the alternative specifications for 휎1푒 . Results in terms of mean posteriorestimates and 90% HPD intervals were almost unchanged in all the cases. Thus, we can assert that model performance was
unaffected by the choice of the value for 휎1푒 .We also observe that theDIC becomes smaller when the standard deviation parameterdecreases and the best-fitting model is the one associated with the smallest values, although the results are hardly different from
both an estimation and convergence perspective for all the parameters.
FIGURE 7 HERE
A.2 Code
The complete JAGS code for the Hurdle Model used in the analysis is given below.
model {
# data variables
# e, c and u denote the QALYs, costs and baseline utilities
# d.e and d.u denote the structural one indicators for e and u
# age, ethnicity and employment are covariates in the model of d.e and d.u
# control group (t = 1)
for(i in 1 : N1) {
# 1. Module for the structural ones in the QALYs
d.e1[i] ~ dbern(pi.e[i, 1])
logit(pi.e[i, 1]) <- gamma0[1] + gamma1[1] * (u1[i] - mean(u1[])) +
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gamma2[1] * (age1[i] - mean(age1[])) + gamma3[ethnicity1[i], 1] + gamma4[employment1[i], 1]
#2. Module for the structural ones in the baseline utilities
d.u1[i] ~ dbern(pi.u[i, 1])
logit(pi.u[i, 1]) <- eta0[1] + eta1[1] * (age1[i] - mean(age1[])) + eta2[ethnicity1[i], 1] + eta3[employment1[i], 1]
#3. Marginal module for the QALYs
e1[i] ~ dbeta(phi.e[i, 1] * tau.e[i, 1], (1 - phi.e[i, 1]) * tau.e[i, 1])
tau.e[i, 1] <- phi.e[i, 1] * (1 - phi.e[i, 1]) / pow(sigma.e[d.e1[i] + 1], 2) - 1
logit(phi.e[i, 1]) <- alpha0[d.e1[i]+1, 1] + alpha1[d.e1[i]+1, 1] * (u1[i] - mean(u1[]))
#4. Marginal module for the baseline utilities
u1[i] ~ dbeta(mu.u[d.u1[i] + 1, 1] * tau.u[d.u1[i] + 1, 1], (1 - mu.u[d.u1[i] + 1, 1]) * tau.u[d.u1[i] + 1, 1])
#5. Conditional module for the costs
c1[i] ~ dgamma(phi.c[i, 1] * tau.c[i, 1], tau.c[i, 1])
tau.c[i, 1] <- phi.c[i, 1] / pow(sigma.c[1], 2)
log( phi.c[i, 1]) <- beta0[1] + beta1[1] * (e1[i] - mu.e[1])
}
#intervention group (t = 2)
for(i in 1 : N2) {
#1. Module for the structural ones in the QALYs
d.e2[i] ~ dbern(pi.e[i, 2])
logit(pi.e[i, 2]) <- gamma0[2] + gamma1[2] * (u2[i] - mean(u2[])) +
gamma2[2] * (age2[i] - mean(age2[])) + gamma3[ethnicity2[i], 2] + gamma4[employment2[i], 2]
#2. Module for the structural ones in the baseline utilities
d.u2[i] ~ dbern(pi.u[i, 2])
logit(pi.u[i, 2]) <- eta0[2] + eta1[2] * (age2[i] - mean(age2[])) + eta2[ethnicity2[i], 2] + eta3[employment2[i], 2]
#3. Marginal module for the QALYs
e2[i] ~ dbeta(phi.e[i, 2] * tau.e[i, 2], (1 - phi.e[i, 2]) * tau.e[i, 2])
tau.e[i,2] <- phi.e[i, 2] * (1 - phi.e[i, 2]) / pow(sigma.e[d.e2[i] + 1], 2) - 1
logit(phi.e[i, 2]) <- alpha0[d.e2[i] + 1, 2] + alpha1[d.e2[i] + 1, 2] * (u2[i] - mean(u2[]))
#4. Marginal module for the baseline utilities
u2[i] ~ dbeta(mu.u[d.u2[i] + 1, 2] * tau.u[d.u2[i] + 1, 2], (1 - mu.u[d.u2[i] + 1, 2]) * tau.u[d.u2[i] + 1, 2])
#5. Conditional module for the costs
c2[i] ~ dgamma(phi.c[i, 2] * tau.c[i, 2], tau.c[i, 2])
tau.c[i, 1] <- phi.c[i, 1] / pow(sigma.c[2], 2)
log( phi.c[i, 2]) <- beta0[2] + beta1[2] * (e2[i] - mu.e[2])
}
#Priors
#priors for module 1 and 2
for(t in 1 : 2) {
gamma0[t] ~ dlogis(0, 1)
gamma1[t] ~ dnorm(0, 0.00001)
gamma2[t] ~ dnorm(0, 0.00001)
eta0[t] ~ dlogis(0, 1)
eta2[t] ~ dnorm(0, 0.00001)
#priors on coefficients for categorical covariates
#(setting reference category as 0)
gamma3[1, t] <- 0
gamma4[1, t] <- 0
eta2[1, t] <- 0
eta3[1, t] <- 0
}
# set priors for all other categories
# use blocking to improve model convergence
# mu and tau values provided as data variables with zero means and small precisions (0.00001)
# ethnicity has different numbers of categories between arms
gamma3[2:14, 1] ~ dmnorm(mu1.gamma3[], tau1.gamma3[, ])
gamma3[2:12, 2] ~ dmnorm(mu2.gamma3[], tau2.gamma3[, ])
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gamma4[2:6, 1] ~ dmnorm(mu1.gamma4[], tau1.gamma4[, ])
gamma4[2:6, 2] ~ dmnorm(mu2.gamma4[], tau2.gamma4[, ])
eta2[2:14, 1] ~ dmnorm(mu1.eta2[], tau1.eta2[, ])
eta2[2:12, 2] ~ dmnorm(mu2.eta2[], tau2.eta2[, ])
eta3[2:6, 1] ~ dmnorm(mu1.eta3[], tau1.eta3[, ])
eta3[2:6, 2] ~ dmnorm(mu2.eta3[], tau2.eta3[, ])
for(t in 1 : 2) {
# priors for model 3
# priors for the ones group in the QALYs
alpha0[2, t] <- logit(0.999999)
alpha1[2, t] <- 0
sigma.e[2, t] <- 0.00001
# priors for the non-ones group in the QALYs
alpha0[1, t] ~ dnorm(0, 0.000001)
alpha1[1, t] ~ dnorm(0, 0.000001)
sigma.e[1, t] ~ dunif(0, sd.limit.e[t])
sd.limit.e[t] <- pow(mu.e[1, t] * (1 - mu.e[1, t]), 0.5)
# priors for model 4
# priors for the ones group in the baseline utilities
tau.u[2, t] <- mu.u[2, t] * (1 - mu.u[2, t]) / pow(sigma.u[2, t], 2) - 1
logit(mu.u[2, t]) <- delta0[2, t]
delta0[2, t] <- logit(0.999999)
sigma.u[2, t] <- 0.00001
# priors for the non-ones group in the baseline utilities
tau.u[1, t] <- mu.u[1,t] * (1 - mu.u[1, t]) / pow(sigma.u[1, t], 2) - 1
logit(mu.u[1, t]) <- delta0[1,t]
delta0[1, t] ~ dnorm(0, 0.00001)
sigma.u[1, t] ~ dunif(0, sd.limit.u[t])
sd.limit.u[t] <- pow(mu.u[1, t] * (1 - mu.u[1, t]), 0.5)
# priors for module 5
beta0[t] ~ dnorm(0, 0.00001)
sigma.c[t] ~ dunif(0, 1000)
beta1[t] ~ dnorm(0, 0.00001)
# obtain marginal probabilities for weighting
p[t] <- ilogit(gamma0[t])
# obtain the weighted marginal mean QALYs
mu.e[t] <- p[t] + (1-p[t]) * ilogit(alpha0[t])
}
# compute incremental QALYs and costs
Delta_e <- mu.e[2] - mu.e[1]
Delta_c <- mu.c[2] - mu.c[1]
}
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FIGURE 1 Histograms of the distributions of the complete case QALYs and costs, expressed in £, in the control (panels a-b)
and intervention (panels c-d) group. For both variables and in both arms, skewness of the observed data is apparent.
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Time Type of outcome Control (푛1=75) Intervention (푛2=84)
observed (%) observed (%)
Baseline utilities 72 (96%) 72 (86%)
3 months utilities and costs 34 (45%) 23 (27%)
6 months utilities and costs 35 (47%) 23 (27%)
12 months utilities and costs 43 (57%) 36 (43%)
complete cases utilities and costs 27 (44%) 19 (23%)
TABLE 1 Number and proportion of observed cases at each time point for the utility and cost data (self-recorded question-
naires), presented by trial group (baseline data only related to the utilities). The number of individuals having valid data at
each time point (complete cases) is also reported at the bottom of the table. Over the trial period both drop-out and intermittent
missingness occur; at each time point only unit-nonresponse patterns are observed.
푐푖
휙푖푐
흍푐
휇푐
[…] 푒푖 휙푖푒
흍푒
휇푒 […]훽1 훼0훽0
Conditional module for 푐
Marginal module for 푒
FIGURE 2 Joint distribution 푝(푒, 푐), expressed in terms of a marginal distribution for the effectiveness and a conditional distri-
bution for the costs, respectively indicatedwith a solid red line and a dashed blue line. The parameters indexing the corresponding
distributions or “modules” are indicated with different Greek letters, while 푖 denotes the individual index. The solid black and
magenta arrows show the dependence relationships between the parameters within and between the two models, respectively.
The dashed magenta arrow indicates that the ancillary parameters of the cost model may be expressed as a function of the corre-
sponding effectiveness parameters. The dots enclosed in the square brackets indicate the potential inclusion of other covariates
at the mean level for both modules.
Scenario Control (푛∗1 = 13) Intervention (푛∗2 = 22)
MNAR1 푑푖푒 = 1 푑푖푒 = 1
MNAR2 푑푖푒 = 0 푑푖푒 = 0
MNAR3 푑푖푒 = 1 푑푖푒 = 0
MNAR4 푑푖푒 = 0 푑푖푒 = 1
TABLE 2 Alternative MNAR scenarios considered in the MenSS study for the Hurdle Model. In each scenario, individuals
who are potentially associated with a unit QALYs in the control (푛∗1 = 13) and intervention (푛∗2 = 22) group are assigned toeither the structural or non-structural components by setting the value of the indicator 푑푖푒 equal to 1 or 0, respectively.
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FIGURE 3 Posterior distributions for the marginal mean parameters of the QALYs (panels a-b) and cost variables (panels c-
d), expressed in £, in each group of the trial under either a complete (red) and all (blue) cases scenario. The posterior results are
presented for all model specifications considered (Bivariate Normal, Beta-Gamma and Hurdle Model) and for each of these the
posterior mean estimates and associated 90% Highest Posterior Density (HPD) interval bounds are reported.
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(a) Bivariate Normal (control)
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(b) Bivariate Normal
(intervention)
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(c) Beta-Gamma (control)
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(d) Beta-Gamma (intervention)
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(e) Hurdle Model (control)
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(f) Hurdle Model (intervention)
FIGURE 4 Imputed QALYs in the control and intervention groups based on the Bivariate Normal, Beta-Gamma and Hurdle
Model. Imputations are summarised in terms of posterior means and 90% HPD intervals (coloured dots and lines) while an x
symbol is used to denote the observed cases. Imputed values are also distinguished according to whether the corresponding
baseline utilities were either observed (blue) or missing (red). The solid black line represents the upper bound for the utilities,
set at the value of 1.
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FIGURE 5 Density strip plots for the posterior distributions of the probability of structural ones (panel a) and the marginal
mean QALYs (panel b) underMAR and four alternativeMNAR scenarios. For each scenario, results are presented for the control
(red) and the intervention (blue) groups. Mean posterior values and associated 90% HPD interval bounds are indicated with tick
marks and reported aside for each quantity.
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(a) Cost-Effectiveness Plane (b) Cost-Effectiveness
Acceptability Curve
FIGURE 6 CEPs (panel a) and CEACs (panel b) associated with the Hurdle (blue dots and line), Bivariate Normal (red dots
and line) and Beta-Gamma (green dots and line) models. In the CEPs, the ICERs based on the results from the three model
specifications under MAR are indicated with corresponding darker coloured dots, while the portion of the plane on the right-
hand side of the straight line passing through the plot (evaluated at 푘 = £20, 000) denotes the sustainability area. For the CEACs,
in addition to the results under MAR (solid lines), the probability values for the four MNAR models described in §4.2 are
represented with different types of dashed lines.
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FIGURE 7 Sensitivity analysis for the choice of the standard deviation for the distribution of the structural ones in the QALYs.
For each value of 휎1푒 tested, posterior means and 90%HPD intervals for the meanQALYs parameters are respectively representedwith dots and lines (red for the control and blue for the intervention group).
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